Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAS siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, Intravenous, Intravitreal, Parenteral
01
Overview
FAS siRNA refers to small interfering RNA (siRNA) designed to target and silence the expression of the Fas cell surface death receptor (Fas, CD95, APO-1). Fas is a member of the tumor necrosis factor receptor superfamily that plays a critical role in programmed cell death (apoptosis). By post-transcriptionally silencing Fas expression, FAS siRNA inhibits Fas-mediated apoptotic pathways, thereby protecting cells from death receptor-induced apoptosis. This therapeutic approach has been investigated in preclinical models for various conditions, including acute liver failure, non-alcoholic steatohepatitis (NASH), diabetic retinopathy, type 1 diabetes, myocardial ischemia-reperfusion injury, and intervertebral disc degeneration.
- Other names
- Fas siRNAFas small interfering RNAsiRNA targeting FAS
02
Targets
TNFR (TNF receptor family)
Beyond the preview
Go deeper on FAS siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAS siRNA.